anti-IL-17 antibody fragment (Cell Medica Switzerland)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-IL-17 antibody fragment (Cell Medica Switzerland)
Drug Alias NameDLX-xxxxanti-IL-17 antibody fragment (Delenex)DLX-3003
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment
Mechanisms of ActionInterleukin-17 inhibitors
TargetsInterleukin-17
Therapy Area/IndicationsPsoriasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCell Medica Switzerland AG
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCell Medica Switzerland AG
Active IndicationsN/A
Inactive IndicationsPsoriasis

Other Information

ATC CodeN/A
Related LinksN/A